chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 17.0
Sex: M
Vaccine: MNQ
Symptoms: Blood test, Muscular weakness, Nuclear magnetic resonance imaging, Pain in extremity, Weight bearing difficulty
Clinical narrative: Sx started as aching pains in the right toes and then right calf, by the month's end he experienced weakness of right leg. When taking stairs, patient is unable to support weight on right leg. Physical therapy ordered and attended.
Age: 17.0
Sex: M
Vaccine: MNQ
Symptoms: X-ray limb
Clinical narrative: Sx started as aching pains in the right toes and then right calf, by the month's end he experienced weakness of right leg. When taking stairs, patient is unable to support weight on right leg. Physical therapy ordered and attended.
Sex: U
Vaccine: VARZOS
Symptoms: Pain in extremity
Clinical narrative: Had leg pain in both legs after vaccine.
Age: 57.0
Sex: F
Vaccine: TDAP
Symptoms: Chest pain, Chills, Dyspnoea, Headache, Heart rate increased
Clinical narrative: Day 2 after shot -> fever, chills, HA. Day 3 after shot - chest pain, SOB, (R) arm swelling, increased pulse.
Age: 57.0
Sex: F
Vaccine: TDAP
Symptoms: Local swelling, Pyrexia
Clinical narrative: Day 2 after shot -> fever, chills, HA. Day 3 after shot - chest pain, SOB, (R) arm swelling, increased pulse.
Age: 24.0
Sex: F
Vaccine: TDAP
Symptoms: Arthralgia, Back pain, Fatigue, Neck pain, Pyrexia
Clinical narrative: Tdap at about 2 pm 6/9/14. On 6/10/14 felt aches in neck, back, hips. Felt feverish in afternoon. Very fatigued. No rash/no local reaction. Felt better by 6/11/14.
Age: 65.0
Sex: F
Vaccine: PPV
Symptoms: Ear pain, Headache, Injection site pain, Injection site swelling, Local swelling
Clinical narrative: 6/9 1800 (L) arm became very painful. 1900 great earaches with pain into head - upper jaw, teeth, back of neck, bad headache and tinnitus. During night, (L) shoulder began swelling and pain from shoulder and clavicle with swelling down (L) arm to hand. Called clinic 6/10 - left msg - call back 1009 - stated swelling was going down arm and shoulder but still has some headaches, not so intense. Did not want to be seen. Would call if symptoms didn't resolve.
Age: 65.0
Sex: F
Vaccine: PPV
Symptoms: Neck pain, Pain in extremity, Pain in jaw, Tinnitus, Toothache
Clinical narrative: 6/9 1800 (L) arm became very painful. 1900 great earaches with pain into head - upper jaw, teeth, back of neck, bad headache and tinnitus. During night, (L) shoulder began swelling and pain from shoulder and clavicle with swelling down (L) arm to hand. Called clinic 6/10 - left msg - call back 1009 - stated swelling was going down arm and shoulder but still has some headaches, not so intense. Did not want to be seen. Would call if symptoms didn't resolve.
Age: 22.0
Sex: F
Vaccine: HEP, HEPA, VARCEL
Symptoms: Immediate post-injection reaction, Injection site erythema, Injection site induration, Injection site pain, Injection site pruritus
Clinical narrative: Came to health dept 6/5/14 to report reaction. States redness and burning right after injection that got worse that night with onset of itching also. Worse the following day and today. Area on posterior (L) upper arm of redness measuring 2 1/2 inches x 3 1/2 inches which is firm and very warm to touch and painful. States nurse did say she was giving it "at an angle". Hx of chickenpox disease but needed for nursing sch.
Age: 22.0
Sex: F
Vaccine: HEP, HEPA, VARCEL
Symptoms: Injection site warmth
Clinical narrative: Came to health dept 6/5/14 to report reaction. States redness and burning right after injection that got worse that night with onset of itching also. Worse the following day and today. Area on posterior (L) upper arm of redness measuring 2 1/2 inches x 3 1/2 inches which is firm and very warm to touch and painful. States nurse did say she was giving it "at an angle". Hx of chickenpox disease but needed for nursing sch.
Age: 4.0
Sex: F
Vaccine: DTAPIPV, MMRV
Symptoms: Injection site induration, Injection site nodule, Injection site pain
Clinical narrative: Father called reported 4-6 cm hard, tender nodular area to left thigh posterior to site of injection.
Age: 5.0
Sex: F
Vaccine: DTAPIPV, MMR, VARCEL
Symptoms: Injection site erythema, Injection site induration, Injection site oedema, Injection site warmth
Clinical narrative: Site on right deltoid following DTaP injection noted redness, warmth, edema, and hardness about 3 cm below injection site. On 6/11/14 area improving, redness 5 x 3 cm, no warmth, slight edema.
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Vaccination site urticaria
Clinical narrative: Local urticaria around (R) thigh vaccine site = MMR and on (L) lower vaccine site = varicella. No swelling or erythema around upper (L) thigh site = Hep A. No other symptoms.
Age: 4.0
Sex: M
Vaccine: DTAP, MMRV
Symptoms: Injection site swelling
Clinical narrative: Pt came in, mom concerned of swollen where vaccine given.
Age: 52.0
Sex: F
Vaccine: TDAP, VARZOS
Symptoms: Erythema, Pain, Skin warm, Tenderness
Clinical narrative: Red, Warm to the touch, Tender, Sore. Advised to use cool compress and Benadryl.
Age: 32.0
Sex: F
Vaccine: TDAP
Symptoms: Abdominal pain upper, Diarrhoea, Dizziness, Fatigue, Nausea
Clinical narrative: Sudden tiredness, stomach cramps, light-headed, dizzy, nausea, vomiting, diarrhea.
Age: 32.0
Sex: F
Vaccine: TDAP
Symptoms: Vomiting
Clinical narrative: Sudden tiredness, stomach cramps, light-headed, dizzy, nausea, vomiting, diarrhea.
Age: 29.0
Sex: F
Vaccine: TDAP
Symptoms: Body temperature increased, Erythema
Clinical narrative: Redness, increased temperature over 50% of upper.  The affected area also went at least 50% around the diameter of the upper arm.
Age: 44.0
Sex: F
Vaccine: TDAP
Symptoms: Injection site swelling, Staphylococcal infection
Clinical narrative: Patient started to have swelling on the injection site.  She states that it happened about a day after immunization was given.
Age: 0.18
Sex: F
Vaccine: DTAP, HEP, HIBV, IPV, PPV, RVX
Symptoms: Crying, Irritability
Clinical narrative: Inconsolable crying and general fussiness, no treatment given, lasted 4 days.
Age: 1.06
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Injection site erythema, Injection site urticaria, Urticaria
Clinical narrative: Hives/erythema confluent around (R) thigh shot site = MMR and lower shot shite in (L) thigh = varicella. No swelling around the HepA site. Child also with urticaria on (R) side of face. No breathing issues. Resolved 3D.
Age: 49.0
Sex: F
Vaccine: VARZOS
Symptoms: Drug administered to patient of inappropriate age, No adverse event
Clinical narrative: NO ADVERSE REACTION AS OF 06/10/2014.
Age: 41.0
Sex: M
Vaccine: HEP
Symptoms: Arthralgia
Clinical narrative: Bilateral knee pain, greater on the left.
Age: 55.0
Sex: M
Vaccine: MMR
Symptoms: Arthralgia, Joint swelling
Clinical narrative: SWELLING AND PAIN IN JOINTS;BEGAN IN FEET/ANKLES ON FRIDAY 6/6; EXPLOSION OF PAIN AND SWELLING ON MONDAY 6/9 IN KNEES, WRISTS/HANDS, SHOULDERS/NECK, WITH EXTREME PAIN IN FEET/ANKLES. SWELLING AND PAIN BEGAN TO SUBSIDE TUESDAY 6/10 PM. BY WEDNESDAY 6/11 CONTINUING TO RECOVER WITH SOME RESIDUAL SWELLING AND PAIN IN WRISTS/HANDS AND KNEES. TOOK 800MG IBUPROFEN EVERY 4-6HRS.
Age: 63.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site pruritus, Injection site reaction, Local reaction, Skin discolouration
Clinical narrative: Originally had local reaction at site of administration of vaccine, red and itchy, resolving; but now reports a single "spot", tender to touch, slightly pink, non-vesicular, non-pustular on face, at jawbone.  Pt reported feeling generally itchy in am when she woke up, also thought there might have been 1 more pink spot on leg and another on back, but not present at 3:20 pm when she called me to report this problem.  Pt advised to show reaction to her primary care physician for evaluation, and will do so tomorrow.
Age: 63.0
Sex: F
Vaccine: VARZOS
Symptoms: Tenderness
Clinical narrative: Originally had local reaction at site of administration of vaccine, red and itchy, resolving; but now reports a single "spot", tender to touch, slightly pink, non-vesicular, non-pustular on face, at jawbone.  Pt reported feeling generally itchy in am when she woke up, also thought there might have been 1 more pink spot on leg and another on back, but not present at 3:20 pm when she called me to report this problem.  Pt advised to show reaction to her primary care physician for evaluation, and will do so tomorrow.
Age: 1.55
Sex: M
Vaccine: HEPA
Symptoms: Granulocyte percentage, Haematocrit normal, Haemoglobin normal, Lymphocyte percentage decreased, Mean cell volume decreased
Clinical narrative: Fever of 105.4.
Age: 1.55
Sex: M
Vaccine: HEPA
Symptoms: Platelet count normal, Pyrexia, Red blood cell count normal, Red cell distribution width normal, Streptococcus test negative
Clinical narrative: Fever of 105.4.
Age: 1.55
Sex: M
Vaccine: HEPA
Symptoms: White blood cell count normal
Clinical narrative: Fever of 105.4.
Age: 62.0
Sex: F
Vaccine: VARZOS
Symptoms: Erythema, Local swelling
Clinical narrative: Patient reported to pharmacist on duty she had a localized, red bump approximately 2 inches in diameter.  Took Benadryl.
Age: 40.0
Sex: F
Vaccine: TDAP
Symptoms: Erythema, Swelling
Clinical narrative: Redness and swelling below the site of injection, starting below the left deltoid muscle and extending to above the elbow.   The patient reported the reaction has gotten progressively worse since the administration.  Patient afebrile and reports no other reactions.
Age: 1.11
Sex: M
Vaccine: DTAP, HEPA, HIBV, MMRV, PNC13
Symptoms: Erythema multiforme
Clinical narrative: Erythema multiforme.
Age: 1.59
Sex: M
Vaccine: MMR
Symptoms: Agitation, Cough, Discomfort, Insomnia, Irritability
Clinical narrative: Fever, fussy, bad cough that came out of nowhere, rash first formed around hairline. Fever and intense rash all over body for 5 days. Child could not sleep. Seemed very uncomfortable and agitated.
Age: 1.59
Sex: M
Vaccine: MMR
Symptoms: Pyrexia, Rash generalised
Clinical narrative: Fever, fussy, bad cough that came out of nowhere, rash first formed around hairline. Fever and intense rash all over body for 5 days. Child could not sleep. Seemed very uncomfortable and agitated.
Sex: F
Vaccine: PPV
Symptoms: Abortion spontaneous, Exposure during pregnancy
Clinical narrative: Information has been reported in a CDC slide. This spontaneous retrospective pregnancy report as received from a registered nurse (RN) in Centers for Disease Control and Prevention (CDC) concerning a female patient of unknown age, 2 of the two patients who experienced spontaneous abortion. On an unknown date, the patient became pregnant. The last menstrual period (LMP) and estimated date of delivery (EDD) was not known. On an unknown date the patient was administered with a dose of PNEUMOVAX 23 (lot#, dose and route were unspecified) during pregnancy. On an unknown date the patient experienced spontaneous abortion. The outcome of spontaneous abortion was unknown. Upon internal review, spontaneous abortion was considered as other medical significant event. This is one of the 18 reports (PNEUMOVAX 23 administered during pregnancy) that received from the same source. Additional information has been requested.
Age: 0.2
Sex: U
Vaccine: HIBV
Symptoms: Convulsion, Crying
Clinical narrative: This spontaneous report was received from a pharmacist refers to a patient of 2 month old and on unknown gender. Medical history was not reported. On an unknown date the patient was vaccinated with PEDVAXHIB injection, lot # J015437, expiration date 09-OCT-2016, route, dosage and frequency were not reported. Concomitant therapy included multiple vaccines unspecified. The reporter informed that on an unknown date the child experienced inconsolable crying and seizures with the lot # J015437. The physician has requested a lot check for this number. The patient sought medical attention by an office visit. Upon internal review the seizures was determined to be medically significant. The patient's outcome with the events was recovering. This is one of several reports received from the same source. Additional information has been requested.
Sex: F
Vaccine: PPV
Symptoms: Abortion spontaneous, Exposure during pregnancy
Clinical narrative: Information has been reported in a CDC slide. This spontaneous retrospective pregnancy report as received from a registered nurse (RN) in Centers for Disease Control and Prevention (CDC) concerning a female patient of unknown age, 1 of the two patients who experienced spontaneous abortion. On an unknown date, the patient became pregnant. The last menstrual period (LMP) and estimated date of delivery (EDD) was not known. On an unknown date the patient was administered with a dose of PNEUMOVAX 23 (lot#, dose and route were unspecified) during pregnancy. On an unknown date the patient experienced spontaneous abortion. The outcome of spontaneous abortion was unknown. Upon internal review, spontaneous abortion was considered as other medical significant event. This is one of the 18 reports (PNEUMOVAX 23 administered during pregnancy) that received from the same source. Additional information has been requested.
Age: 65.0
Sex: F
Vaccine: PPV, TDAP
Symptoms: Abdominal pain upper, Pain, Pyrexia
Clinical narrative: Patient submitted a written statement stating after she received a PNEUMOVAX and ADACEL on 06/06/14, she developed a fever in the evening that lasted 24 hrs. On 06/07/14 evening patient developed upper abdominal pain and body aches. On 06/08/14 patient stated s/sx resolved.
Age: 63.0
Sex: F
Vaccine: HEPAB, PPV, TDAP
Symptoms: Injection site cellulitis
Clinical narrative: Cellulitis on left arm from pneumonia vaccine.
Age: 23.0
Sex: F
Vaccine: DTAP
Symptoms: Exposure during pregnancy, Pregnancy test positive, Wrong drug administered
Clinical narrative: Pt here for pregnancy verification. Positive pregnancy screen. Normal signs of pregnancy. Sore breasts, nausea, small amount of cramping. No spotting or other danger signs. Pt had no PMD assess currently - to establish with department at some later date. Wanted Tdap. DTaP was inadvertently given.
Age: 48.0
Sex: F
Vaccine: PPV
Symptoms: Mass, Mobility decreased, Pain
Clinical narrative: 10cm x 9cm mass after 230pm. Some deg sore difficult to raise arm.
Age: 4.0
Sex: F
Vaccine: DTAP, MMR
Symptoms: Erythema, Induration
Clinical narrative: 5.5 x 5 in red patch. 7 x 7.5 in induration and redness.
Age: 13.0
Sex: F
Vaccine: HPV4
Symptoms: Feeling hot, Pruritus, Rash, Urticaria
Clinical narrative: Rash, hives, excessive warmth of face, itchiness.
Age: 0.83
Sex: M
Vaccine: PNC13
Symptoms: Injection site urticaria, Pyrexia, Rash, Urticaria
Clinical narrative: Per mother child developed hives on arms and legs and fever - up to 102 about 1 hour after receiving vaccine on 6/9/14. Evaluated by ARNP today - rash and fever continues.
Age: 70.0
Sex: M
Vaccine: PPV
Symptoms: Injection site discomfort, Injection site erythema, Injection site swelling
Clinical narrative: Swelling, redness, discomfort in left upper arm.
Age: 0.33
Sex: M
Vaccine: DTAPHEPBIP, HIBV, PNC13, RV5
Symptoms: Abdominal X-ray, Enema administration, Haematochezia, Intussusception, Vomiting
Clinical narrative: Pt presented with intussusception 3 days following vaccination with emesis and bloody stool. Reduced by fluoroscopy and air enema.
Age: 0.33
Sex: M
Vaccine: DTAPHEPBIP, HIBV, PNC13, RV5
Symptoms: X-ray abnormal
Clinical narrative: Pt presented with intussusception 3 days following vaccination with emesis and bloody stool. Reduced by fluoroscopy and air enema.
Age: 92.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster, Paraesthesia, Rash
Clinical narrative: Shingles type rash developed 6/10/14 under (R) breast radiating to (R) back tingling sensation - Dr Dx - shingles with rx for acyclovir.
Sex: U
Vaccine: RV5
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to 2 patients of unknown age. No concomitant were reported. On 21-MAY-2014, the patients were vaccinated with ROTATEQ INJ, lot J015062, expiration date 13-OCT-2015 )dose, frequency, route of administration and indication were not provided) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013915 and 1405USA013916, 1405USA0139151406USA004906, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004881, 1406USA004891, 1406USA004896, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837 by the same reporter link. Additional information is not expected.
Sex: F
Vaccine: PPV
Symptoms: Cellulitis, Exposure during pregnancy
Clinical narrative: Information has been reported in a CDC slide titled as "Safety of PNEUMOVAX 23 in the Vaccine Adverse Reporting System (VAERS)". This spontaneous prospective pregnancy report as received from a registered nurse (RN) in Centers for Disease Control and Prevention (CDC) concerning a female patient of unknown age, 1 of the six patients who experienced cellulitis. On an unknown date, the patient became pregnant. The last menstrual period (LMP) and estimated date of delivery (EDD) was not known. On an unknown date the patient was administered with a dose of PNEUMOVAX 23 (lot#, dose and route were unspecified) during pregnancy. On an unknown date the patient experienced cellulitis. The outcome of cellulitis was unknown. The pregnancy outcome was unknown. This is one of the 18 reports (PNEUMOVAX 23 administered during pregnancy) that received from the same source. Additional information has been requested.
Sex: F
Vaccine: PPV
Symptoms: Exposure during pregnancy, No adverse event
Clinical narrative: Information has been reported in a CDC slide titled as "Safety of PNEUMOVAX 23 in the Vaccine Adverse Reporting System (VAERS)". This spontaneous prospective pregnancy report as received from a registered nurse (RN) in Centers for Disease Control and Prevention (CDC) concerning a female patient of unknown age, 2 of the four patients who experienced no adverse event. On an unknown date, the patient became pregnant. The last menstrual period (LMP) and estimated date of delivery (EDD) was not known. On an unknown date the patient was administered with a dose of PNEUMOVAX 23 (lot#, dose and route were unspecified) during pregnancy. No adverse event reported. The outcome of pregnancy was unknown. The pregnancy outcome was unknown. This is one of the 18 reports (PNEUMOVAX 23 administered during pregnancy) that received from the same source. Additional information has been requested.
Age: 21.0
Sex: F
Vaccine: VARCEL
Symptoms: Abdominal discomfort, Exposure during pregnancy, Genital lesion, Vaginal discharge
Clinical narrative: This spontaneous prospective pregnancy report as received from a registered nurse refers to a 21 year old female patient with unconfirmed lupus in July 2013. The patient presented to her facility on 29-APR-2014 for Sexual Transmitted Disease (STD) testing and treatment, reporting that she was pregnant. During the patient's physical exam, her blood pressure was 76/53 on two attempts. The patient reported feeling "dizzy and faint" and she was instructed to go to her primary care physician for examination and to consult an obstetrician for management of her pregnancy. On 22-MAY-2014, the patient returned to the facility reporting that she was required to receive VARIVAX and TDAP for an employment requirement. On that date, the patient denied being pregnant, and she received VARIVAX, 0.5 ml, subcutaneous in the right arm for routine vaccination (was not reported if the patient received TDAP). Concomitant medication included "prenatal vitamins". On 29-MAY-2014, the patient returned to facility reporting that she was pregnant. The patient became pregnant on an unknown date. The LMP and EDD were not known. On 29-MAY-2014, the patient experienced discomfort in her abdominal region. Patient was examined, and the nurse reported that the patient had copious vaginal discharge and multiple macerated lesions in the genital area. The nurse could not determine from the exam if the lesions were vesicular or pustular, due to the amount of discharge that the patient was experiencing. The nurse did not confirm pregnancy during the examination. The outcome of the events was reported as not recovered. The pregnancy outcome was unknown. Additional information has been requested.
Sex: F
Vaccine: PPV
Symptoms: Exposure during pregnancy, No adverse event
Clinical narrative: Information has been reported in a CDC slide titled as "Safety of PNEUMOVAX 23 in the Vaccine Adverse Reporting System (VAERS)". This spontaneous prospective pregnancy report as received from a registered nurse (RN) in Centers for Disease Control and Prevention (CDC) concerning a female patient of unknown age, 1 of the four patients who experienced no adverse event. On an unknown date, the patient became pregnant. The last menstrual period (LMP) and estimated date of delivery (EDD) was not known. On an unknown date the patient was administered with a dose of PNEUMOVAX 23 (lot#, dose and route were unspecified) during pregnancy. No adverse event reported. The outcome of pregnancy was unknown. The pregnancy outcome was unknown. This is one of the 18 reports (PNEUMOVAX 23 administered during pregnancy) that received from the same source. Additional information has been requested.
Sex: F
Vaccine: PPV
Symptoms: Exposure during pregnancy, Local reaction
Clinical narrative: Information has been reported in a CDC slide titled as "Safety of PNEUMOVAX 23 in the Vaccine Adverse Reporting System (VAERS)". This spontaneous prospective pregnancy report as received from a registered nurse (RN) in Centers for Disease Control and Prevention (CDC) concerning a female patient of unknown age, 5 of the five patients who experienced local reactions. On an unknown date, the patient became pregnant. The last menstrual period (LMP) and estimated date of delivery (EDD) was not known. On an unknown date the patient was administered with a dose of PNEUMOVAX 23 (lot#, dose and route were unspecified) during pregnancy. On an unknown date the patient experienced local reactions. The outcome of local reactions was unknown. The pregnancy outcome was unknown. This is one of the 18 reports (PNEUMOVAX 23 administered during pregnancy) that received from the same source. Additional information has been requested.
Age: 12.0
Sex: M
Vaccine: HPV4
Symptoms: Inappropriate schedule of drug administration, No adverse event
Clinical narrative: This spontaneous report as received from a nurse practitioner refers to an approximately 13 year old male patient. Pertinent medical history and drug reactions/allergies were not reported. In 2014, the patient was in the office to receive his second dose of GARDASIL 0.5 ml intramuscular; however, patient had received first dose of GARDASIL 0.5 ml intramuscular on 27-JUN-2013. No adverse event was reported. Co-suspect therapy was not reported. Concomitant therapy was not reported. Additional information has been requested.
Age: 4.0
Sex: F
Vaccine: MMR
Symptoms: Lethargy, Pyrexia
Clinical narrative: This spontaneous report was received from the patient's mother refers to her daughter a 4 year old female patient. Patient with no drug reactions or allergies. Patient has Down's Syndrome. On an unknown date (several years ago) the patient was vaccinated with the first dose of MMR II (route, lot number and expiration date not reported). There was no concomitant medication reported. Patient's mother reported that when the patient received MMR II she experienced fever and was lethargic on an unknown date. Patient sought for medical attention: unspecified contact. No lab diagnostic studies were performed. These symptoms lasted for about a week and then recovered on an unknown date. It was reported that events occurred several years ago when family was living in another city. It was also reported that the patient had not received dose 2 of MMR II. This is one of two reports from the same source (sibling MARRS # 1406USA003598). Additional information is not expected.
Sex: M
Vaccine: VARZOS
Symptoms: Drug administered at inappropriate site
Clinical narrative: This spontaneous report was received from a pharmacist refers to a male patient of unknown age. Medical history was not reported. On 29-MAY-2014 the patient was vaccinated with ZOSTAVAX, subcutaneous in the right buttock, lot number, strength and dosage were not reported. Concomitant therapy was not reported. The pharmacist informed that on 29-MAY-2014, he went to give to the patient the shot and the patient could not take the shot in his arms and requested in his buttock below the waist and above imaginary line above butt crack on the outer right buttock. The pharmacist used 5/8th needle and used 45 degree angle and inserted the whole needle and gave the shot. The pharmacist asked if he did anything wrong. Additional information has been requested.
Age: 76.0
Sex: M
Vaccine: PPV
Symptoms: Expired drug administered, No adverse event
Clinical narrative: This spontaneous report as received from a healthcare worker refers to a 76 year old male patient. Medical history was not reported. On 29-MAY-2014 the patient was vaccinated with PNEUMOVAX 23 (lot number: H018989, expiration date: 12-MAR-2014, dose number, dose, units, route of administration, anatomical location was not reported). The reporter stated that she inadvertently administered expired PNEUMOVAX 23 to a pateint on 29-MAY-2014. No adverse effects were reported. Additional information has been requested.
Sex: F
Vaccine: PPV
Symptoms: Exposure during pregnancy, No adverse event
Clinical narrative: Information has been reported in a CDC slide titled as "Safety of PNEUMOVAX 23 in the Vaccine Adverse Reporting System (VAERS)". This spontaneous prospective pregnancy report as received from a registered nurse (RN) in Centers for Disease Control and Prevention (CDC) concerning a female patient of unknown age, 3 of the four patients who experienced no adverse event. On an unknown date, the patient became pregnant. The last menstrual period (LMP) and estimated date of delivery (EDD) was not known. On an unknown date the patient was administered with a dose of PNEUMOVAX 23 (lot#, dose and route were unspecified) during pregnancy. No adverse event reported. The outcome of pregnancy was unknown. The pregnancy outcome was unknown. This is one of the 18 reports (PNEUMOVAX 23 administered during pregnancy) that received from the same source. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: This spontaneous report was received from a pharmacist, via a company representative, concerning a male patient of unknown age. Medical history and concurrent conditions were not reported. In 2013 (reported as received the vaccine about one year ago) the patient was vaccinated with a dose of ZOSTAVAX (dose reported a single shot)(strength, lot number, expiration date and route were not reported). Co-suspect and concomitant therapies were not reported. The pharmacist reported that, "an anonymous patient (demographics unknown) received the ZOSTAVAX vaccine about 1 year ago (specific date unknown)(approximately in 2013) and got shingles 2 weeks after receiving the ZOSTAVAX vaccine. At the time of the report the outcome was unknown. Additional information has been requested.
Age: 1.5
Sex: M
Vaccine: MMR
Symptoms: Lethargy, Pyrexia
Clinical narrative: This spontaneous report was received from the patient's mother refers to her son a 18 month old male patient. Patient with no drug reactions, allergies or pertinent medical history. On an unknown date (several years ago) the patient was vaccinated with the first dose of MMR II (route, lot number and expiration date not reported). There was no concomitant medication reported. Patient's mother reported that when the patient received MMR II he experienced fever and was lethargic on an unknown date. Patient sought for medical attention: unspecified contact. No lab diagnostic studies were performed. These symptoms lasted for about a week and then recovered on an unknown date. It was reported that events occurred several years ago when family was living in another city. It was also reported that the patient had not received dose 2 of MMR II. This is one of two reports from the same source (sibling MARRS # 1406USA005661). Additional information is not expected.
Age: 18.0
Sex: F
Vaccine: HPV4
Symptoms: Arthralgia, Rheumatoid arthritis
Clinical narrative: This spontaneous report was received from a physician via field employee, refers to a 18 year old female patient. Medical history was not reported. In January 2011 the patient was vaccinated with GARDASIL dose 3, dosage, lot number and strength were not reported, for prevention of human papilloma virus (HPV). Concomitant therapy was not reported. The physician informed that on 25-JAN-2011 the patient presented to his office with a joint pain, also reported that the patient was diagnosed with rheumatoid arthritis on an unspecified date in February 2011. The patient sought medical attention by a physician's office visit. The outcome of the event was reported as not recovered. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Vaccination complication
Clinical narrative: This spontaneous report as received from a physician refers to a patient of unknown age and gender. On an unknown date, the patient was vaccinated with ZOSTAVAX (dose, route and lot number were not reported). Concomitant medications were not reported. On an unknown date the patient had a reaction to ZOSTAVAX. The outcome of the reaction to ZOSTAVAX was not reported. The relationship between ZOSTAVAX and the event was related. Additional information has been requested.
Sex: F
Vaccine: HPV4
Symptoms: Oropharyngeal pain
Clinical narrative: This spontaneous report was received from a physician concerning a female patient of unknown age. Medical history and concurrent conditions were not reported. On an unknown date the patient was vaccinated with a dose of GARDASIL (strength, lot number, expiration date and route were not reported) dose 1. Co-suspect and concomitant therapies were not reported. Physician reported that an unspecified patient experienced a sore throat "1 month after" receiving her 1st dos of GARDASIL. At the time of the report the outcome was unknown. Additional information has been requested.
Sex: U
Vaccine: RV5
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to a patient of unknown age. No concomitant were reported. On an unknown date, the patient was vaccinated with ROTATEQ INJ, lot K001715, expiration date 14-NOV-2015 (dose, frequency, route of administration and indication were not provided)) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report in linked to 1405USA013915 and 1405USA013916, 1405USA013915, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004874, 1406USA004881, 1406USA004891, 1406USA004896, 1406USA004897, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837 by the same reporter link.
Sex: U
Vaccine: HEPA
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to a patient of unknown age. No concomitants were reported. On 22-MAY-2014, the patient was vaccinated with VAQTA INJ, lot K000943, expiration date 26-SEP-2016 (dose, frequency, route of administration and indication were not reported) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013915 and 1405USA0139161406USA004906, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004881, 1406USA004891, 1406USA004896, 1406USA004897, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA0048371405USA013915 by the same reporter link. Additional information is not expected.
Age: 55.0
Sex: M
Vaccine: HEP
Symptoms: Expired drug administered, No adverse event
Clinical narrative: This spontaneous report as received from a healthcare professional, concerning a 55 year old male patient. Medical history and concurrent conditions were not reported. On 02-JUN-2014, the patient was vaccinated with a dose RECOMBIVAX HB, 1 ml, intramuscular, lot number H017800, expiration date 01-JUN-2014, for vaccination. Co-suspect and concomitant therapies were not reported. On 02-JUN-2014 healthcare professional stated a colleague vaccinated an adult client with expired RECOMBIVAX HB today. No adverse effects reported at this time. Additional information has been requested.
Sex: U
Vaccine: HEPA
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to a patient of unknown age. No concomitants were reported. On 15-MAY-2014, the patient was vaccinated with VAQTA inj, lot K000943, expiration date 26-SEP-2016 (dose, frequency, route of administration and indication were not provided) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013915 and 1405USA013916 1406USA004906, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004881, 1406USA004891, 1406USA004896, 1406USA004897, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837 by the same reporter link. Additional information is not expected.
Sex: U
Vaccine: MMR
Symptoms: Drug administered at inappropriate site, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to unspecified number of patients of unknown age. On an unknown date the patients were vaccinated with MMR II (lot#, expiration date, dose, were unknown), subcutaneous in the thigh, rather than the outer aspect of the upper arm. No adverse effects reported. Additional information is not expected.
Sex: U
Vaccine: MMR
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report received from a healthcare worker refers to a unknown number of patients of unknown age and gender. Since 23-MAY-2014 the suspect vaccines were improperly stored and on unknown date (in approximately May 2014) the patients were vaccinated with M-M-R II Lot #, dosage, anatomical localization and route of administration were not reported. Vaccines has been administered up to 8 patients. No adverse effects reported. This is one of the several reports of the same source. Additional information has been requested.
Sex: U
Vaccine: MMRV
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report received from a healthcare worker refers to a unknown number of patients of unknown age and gender. Since 23-MAY-2014 the suspect vaccines were improperly stored and on unknown date (in approximately May 2014) the patients were vaccinated with PROQUAD, Lot #, dosage, anatomical localization and route of administration were not reported. Vaccines has been administered up to 8 patients. No adverse effects reported. This is one of several reports of the same source. Additional information has been requested.
Sex: U
Vaccine: HIBV
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to 2 patients of unknown age. No concomitants were reported on 19-MAY-2014, patients were vaccinated with LIQUID PEDVAXHIB (dose, frequency, route of administration and indication were not provided) Lot # J016188, expiration date 02-OCT-2016 that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. No further information provided. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013338, 1405USA013916, 1405USA013915, 1406USA004906, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004881, 1406USA004891, 1406USA004896, 1406USA004897, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837 by the same reporter link. Additional information is not expected.
Sex: U
Vaccine: HIBV
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report received from a healthcare worker refers to a unknown number of patients of unknown age and gender. Since 23-MAY-2014 the suspect vaccines were improperly stored and on unknown date (in approximately May 2014) the patients were vaccinated with LIQUID PEDVAXHIB Lot #, dosage, anatomical localization and route of administration were not reported. Vaccines has been administered up to 8 patients. No adverse effects reported. This is one of the several reports of the same source. Additional information has been requested.
Sex: U
Vaccine: RV5
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to 1 patient of unknown age. No concomitant were reported. On 15-MAY-2014, the patient was vaccinated with ROTATEQ INJ, lot J015062, expiration date 13-OCT-2015 (dose, frequency, route of administration and indication were not provided) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a  phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013915 and 1405USA0139161406USA004906, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004881, 1406USA004891, 1406USA004896, 1406USA004897, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837, 1405USA013915 by the same reporter link. Additional information is not expected.
Sex: U
Vaccine: RV5
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to a patient of unknown age. No concomitants were reported. On 16-MAY-2014, the patient was vaccinated with ROTATEQ inj, lot J015062, expiration date 13-OCT-2015 (dose, frequency, route of administration and indication were not provided) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013915 and 1405USA013916, 1406USA004906, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004891, 1406USA004896, 1406USA004897, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837 by the same reporter link. Additional information is not expected.
Sex: U
Vaccine: HEPA
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from nurse refers to 2 patients of unknown age. No concomitants were reported. On 23-MAY-2014, the patients were vaccinated with VAQTA INJ, K000943, expiration date 26-SEP-2016 (dose, frequency, route of administration and indication were not provided) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013915 and 1405USA013916, 1406USA004906, 1406USA004908, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004881, 1406USA004891, 1406USA004896, 1406USA004897, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837 by the same reporter link. Additional information is not expected.
Sex: U
Vaccine: RV5
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to 5 patients of unknown age. No concomitants were reported. On 20-MAY-2014, the patients were vaccinated with ROTATEQ inj, lot J015062, expiration date 13-OCT-2015 (dose, frequency, route of administration and indication were not provided) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013915 and 1405USA013916, 1406USA004906, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004881, 1406USA004891, 1406USA004897, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837 by the same reporter link. Additional information is not expected.
Sex: U
Vaccine: RV5
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to a patient of unknown age. No concomitants were reported. On 19-MAY-2014, the patient was vaccinated with ROTATEQ INJ, lot J015062, expiration date 13-OCT-2015 (dose, frequency, route of administration and indication were not provided) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013915 and 1405USA013916, 1406USA004906, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004881, 1406USA004896, 1406USA004897, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837 by the same reporter link. Additional information is not expected.
Sex: U
Vaccine: RV5
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to 2 patients of unknown age. No concomitants were reported. On 23-MAY-2014, the patients were vaccinated with ROTATEQ INJ, lot J015062, expiration date 13-OCT-2015 (dose, frequency, route of administration and indication were not provided) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013915 and 1405USA013916, 1405USA013915, 1406USA004906, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004963, 1406USA004874, 1406USA004881, 1406USA004891, 1406USA004896, 1406USA004897, 1409USA004900, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837 by the same reporter link. Additional information is not expected.
Sex: U
Vaccine: HIBV
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to 3 patients of unknown age. No concomitants were reported. On 16-MAY-2014, the patients were vaccinated with LIQUID PEDVAXHIB (dose, frequency, route of administration and indication were not provided) lot# J016188, expiration date 02-OCT-2016 that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013338 and 1405USA013916, 1405USA013915, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004881,1406USA004891, 1406USA004896, 1406USA004897, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837 by the same reporter link. Additional information is not expected.
Sex: U
Vaccine: HEPA
Symptoms: Incorrect storage of drug, No adverse event
Clinical narrative: This spontaneous report as received from a nurse refers to 5 patients of unknown age. No concomitants were reported. On 20-MAY-2014, the patients were vaccinated with VAQTA INJ, lot K000943, expiration date 26-SEP-2016 (dose, frequency, route of administration and indication were not provided) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013915 and 1405USA013916 1406USA004906, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004881, 1406USA004891, 1406USA004896, 1406USA004897, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004833, 1406USA004835, 1406USA004837, 1405USA013915 by the same reporter.